{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment+-+Cohort+3&page=18",
    "query": {
      "intervention": "Combination Treatment - Cohort 3",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 1069,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment+-+Cohort+3&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment+-+Cohort+3&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T14:08:55.721Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05627960",
      "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Hormone-Resistant Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "AG-01 Compound",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "A&G Pharmaceutical Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2022-02-14",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2022-11-28",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05627960"
    },
    {
      "nct_id": "NCT02255162",
      "title": "Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Acute Myelocytic Leukemia",
        "Acute Myelogenous Leukemia",
        "Acute Granulocytic Leukemia",
        "Acute Non-Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "HLA-mismatched stem-cell Microtransplantation",
          "type": "GENETIC"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 8,
      "start_date": "2015-01",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02255162"
    },
    {
      "nct_id": "NCT04539470",
      "title": "Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Efmarodocokin Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2020-11-19",
      "completion_date": "2023-02-24",
      "has_results": false,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Los Angeles, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04539470"
    },
    {
      "nct_id": "NCT03878927",
      "title": "CPX-351+GO in Subjects 55 Years Old, or Older, With AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "CPX-351",
          "type": "DRUG"
        },
        {
          "name": "Gemtuzumab Ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-08-23",
      "completion_date": "2022-09-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-10",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03878927"
    },
    {
      "nct_id": "NCT03281369",
      "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma"
      ],
      "interventions": [
        {
          "name": "5-Fluorouracil (5-FU)",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "PEGylated recombinant human hyaluronidase (PEGPH20)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BL-8040",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2017-10-13",
      "completion_date": "2025-10-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03281369"
    },
    {
      "nct_id": "NCT01332266",
      "title": "E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "E7050",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2011-09-19",
      "completion_date": "2017-09-04",
      "has_results": true,
      "last_update_posted_date": "2022-01-03",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 7,
      "location_summary": "Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01332266"
    },
    {
      "nct_id": "NCT04630756",
      "title": "AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Haematological Malignancies"
      ],
      "interventions": [
        {
          "name": "AZD4573",
          "type": "DRUG"
        },
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 40,
      "start_date": "2021-02-17",
      "completion_date": "2025-02-27",
      "has_results": true,
      "last_update_posted_date": "2025-04-09",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 4,
      "location_summary": "Duarte, California • La Jolla, California • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04630756"
    },
    {
      "nct_id": "NCT07464951",
      "title": "CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Anti-CD123 LV redirected T cells (CART123)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ruxolitinib (JAKAVI®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Stephan Grupp MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "0 Years to 29 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-05-14",
      "completion_date": "2030-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07464951"
    },
    {
      "nct_id": "NCT04691375",
      "title": "A Study of PY314 in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Gynecologic Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Lung Adenocarcinoma",
        "Renal Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "PY314",
          "type": "DRUG"
        },
        {
          "name": "Combination Therapy: PY314 + Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2020-10-29",
      "completion_date": "2023-09-22",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04691375"
    },
    {
      "nct_id": "NCT00770536",
      "title": "AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Carcinoma",
        "Fallopian Tube Cancer",
        "Gynecological Malignancies",
        "Metastases",
        "Oncology",
        "Ovarian Cancer",
        "Solid Tumors",
        "Tumors"
      ],
      "interventions": [
        {
          "name": "A1: AMG 386 10 mg/kg + Liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "A3: AMG 386 15mg/kg + Liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "B1: AMG 386 10 mg/kg + Topotecan",
          "type": "DRUG"
        },
        {
          "name": "B3: AMG 386 15mg/kg + Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 103,
      "start_date": "2009-01",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2015-09-29",
      "last_synced_at": "2026-10-15T14:08:55.721Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Sacramento, California • Orlando, Florida + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00770536"
    }
  ]
}